)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Ensysce Biosciences
Ensysce Biosciences (ENSC) investor relations material
Ensysce Biosciences Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary4 Jun, 2026
Company overview and business model
Operates in the biosciences sector, focusing on the development and commercialization of pharmaceutical products.
Engages in product development and commercial manufacturing through agreements with third parties.
Relies on third-party contract research organizations for research, development, and clinical trials.
Financial performance and metrics
Has incurred substantial net losses and negative cash flows since inception, with continued losses expected as R&D and regulatory efforts persist.
Current cash on hand is sufficient to fund operations into the late second quarter of 2026.
Auditor's report includes a going concern uncertainty due to liquidity constraints.
Stock price has been highly volatile, ranging from $0.23 to $2.75 per share over the past year.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling securityholders; proceeds go directly to those holders.
Company bears registration and compliance costs, while selling securityholders pay commissions and discounts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ensysce Biosciences
- Net loss of $3.6 million and clinical progress in Q1 2026 amid cash constraints.ENSC
Q1 202615 May 2026 - Advancing opioid analgesics with anti-abuse and overdose protection, led by PF614 and PF614-MPAR.ENSCInvestor presentation22 Apr 2026
- Urgent capital needs, dilution risk, and Nasdaq compliance challenges amid large resale registration.ENSCRegistration filing9 Apr 2026
- Advanced Phase 3 programs and expanded IP, with net loss rising to $10.2M on higher R&D.ENSCQ4 202530 Mar 2026
- All proposals passed and clinical programs advanced, setting the stage for a pivotal year.ENSCAGM 20257 Jan 2026
- Next-gen opioid therapies with anti-abuse and overdose protection advance toward market launch.ENSCInvestor Presentation7 Jan 2026
- Key votes on stock issuance, incentive plan, directors, and auditor set for January 7, 2026.ENSCProxy Filing16 Dec 2025
- Registers 4.6M shares for warrant/preferred conversion; faces liquidity and dilution risks.ENSCRegistration Filing16 Dec 2025
- Registering 29.5M shares underlying new warrants amid going concern and Nasdaq compliance risks.ENSCRegistration Filing16 Dec 2025
Next Ensysce Biosciences earnings date
Q2 202614 Aug, 2026
Ensysce Biosciences
Next Ensysce Biosciences earnings date
Q2 202614 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage